Moleculin Biotech (NASDAQ:MBRX) reported first quarter results for 2023.
- Moleculin Biotech reported a loss per share of 28 cents.
- That was worse than the analyst estimate for a loss of 25 cents.
- The company did not report any revenue for the quarter.
- You can read the full Moleculin Biotech press release here.
On the date of publication, Sarah Smith did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Sarah Smith is the Editor-in-Chief of InvestorPlace.com.
